IP Library Granted Patent US 7,192,583
Granted Patent B2
US 7,192,583 · App. 10/384,893 · Granted Mar 20, 2007

Methods for modulating bone mineralization

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,192,583
App. No.
10/384,893
Granted
Mar 20, 2007
Kind
B2
Abstract

Antibodies to a novel family of TGF-β binding proteins are disclosed, for use in methods of altering bone density and bone mineralization, which methods are applicable to the treatment of diseases including osteopenia and osteoporosis.

Claims (10)

1. A method for altering bone mineral density, comprising administering to an individual a therapeutically effective amount of an antibody that binds to a BEER polypeptide and increases bone density wherein the BEER polypeptide is selected from the group consisting of:

(a) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 9, 11, 13, and 15, and

(b) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 10, 12, 14, and 16.

2. The method of claim 1 wherein the antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a humanized antibody, F(ab′)2, F(ab) 2 , Fab′, Fab, and Fv.

3. A method for treating a condition which results in loss of bone mineral content, comprising administering to an individual a therapeutically effective amount of an antibody that binds to a BEER polypeptide and increases bone density wherein the BEER polypeptide is selected from the group consisting of:

(a) a polypeptide encoded by a polynucleotide that comprises a nucleotide sequence selected from SEQ ID NOs:1, 5, 9, 11, 13, and 15, and

(b) a polypeptide that comprises an amino acid sequence selected from SEQ ID NOs: 2, 6, 10, 12, 14, and 16,

wherein bone mineral content is increased.

4. The method of claim 3 wherein the condition which results in loss of bone mineral content is selected from the group consisting of osteopenia and osteoporosis.

5. The method of claim 3 wherein the condition which results in loss of bone mineral content is selected from the group consisting of bone dysplasia and bone fracture.

Assignments (4)
NUNC PRO TUNC ASSIGNMENT Recorded Oct 25, 2013
From: DARWIN DISCOVERY LIMITED
To: UCB S.A.
Reel/Frame 031479/0219 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 25, 2013
From: UCB S.A.
To: UCB PHARMA S.A.
Reel/Frame 031479/0358 →
DISSOLUTION OF CELLTECH R&D, INC. AND SUBSEQUENT DISTRIBUTION OF ASSETS INTO DARWIN MOLECULAR CORPORATION Recorded Sep 29, 2010
From: CELLTECH R&D, INC.
To: DARWIN MOLECULAR CORPORATION
Reel/Frame 025051/0949 →
MERGER Recorded Sep 29, 2010
From: DARWIN MOLECULAR CORPORATION
To: UCB MANUFACTURING, INC.
Reel/Frame 025051/0957 →